Stockscreener 앱 받기
1.06
2.75%
-0.03
시간 외 거래:
1.06
Phio Pharmaceuticals Corp 주식(PHIO)의 최신 뉴스
Phio Pharmaceuticals Corp. SEC Filing (Aug 14, 2026) - Stock Titan
Phio Pharmaceuticals Corp (NASDAQ: PHIO) Share Price, PHIO Stock News, PHIO Share Price & Updates - Kalkine
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Compound PH-894 Targeting BRD4 Protein - The National Law Review
Phio Pharmaceuticals receives U.S. patent allowance for PH-894 - Investing.com
Phio Pharma wins U.S. patent allowance for BRD4-targeting INTASYL compound PH-894 - Bitget
Phio Pharmaceuticals Receives U.S. Notice of Allowance for PH-894 Patent Targeting BRD4 Protein via INTASYL® Platform - kalkine.ca
Enterprise value to revenue forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Phio Pharmaceuticals Corp (PHIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Phio Pharmaceuticals Corp. Q2 2026: Net income $(4.14)M, EPS $(0.36) — 10-Q Summary - TradingView
Phio Pharmaceuticals posts $4.1M Q2 net loss, cash $13.0M; advances PH-762 program - TradingView
PHIO: PH-762 clinical progress accelerates as cash runway extends into 2027 amid rising R&D costs - TradingView
PHIO: Q2 2026 net loss widened to $4.1M as PH-762 advanced, with $13M in cash and ongoing funding needs - TradingView
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update - TMX Newsfile
Phio intends to request an FDA meeting after 22-patient cancer study - Stock Titan
PHIO Q2'26 Earnings: EPS estimate is (0.36) USD - TradingView
Phio Pharmaceuticals (PHIO) Rises 2.91% as Shares Hold Above Key $1.01 SupportPost-Earnings Moves - dars.gov.et
Phio Pharmaceuticals (NASDAQ:PHIO) secures patent milestone as PH-762 skin cancer program nears FDA meeting - Kalkine
PHIO Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - TMX Newsfile
Phio Pharmaceuticals Corp (PHIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Phio Pharmaceuticals Corp (PHIO) Cash Flow - TradingKey
PHIO|Phio Pharmaceuticals Corp|Price:1.050| - TradingKey
TradingKey - TradingKey
Phio Pharmaceuticals Corp (PHIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Phio Pharmaceuticals Market Sentiment - Benzinga España
Phio Pharmaceuticals Corp. Revenue Breakdown – NASDAQ:PHIO - TradingView
PHIO|Phio Pharmaceuticals Corp|Price:1.040| - TradingKey
PHIO|Phio Pharmaceuticals Corp|Price:1.055|Chg%:+0.015 - TradingKey
Phio Pharmaceuticals Corp (PHIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Phio Pharmaceuticals (PHIO) Edges Higher, Testing Key Resistance at $1.13Sector ETF Flow - dars.gov.et
Phio Pharma corrects date for Renmark virtual non-deal roadshow presentation - Bitget
Phio Pharmaceuticals to present its INTASYL siR... - Pluang
Phio Pharmaceuticals CEO Robert Bitterman to Showcase INTASYL Gene Silencing Platform at Renmark Virtual Roadshow on July 28, 2026 - Kalkine Media
Phio Pharmaceuticals to Showcase INTASYL siRNA Platform and PH-762 Skin Cancer Therapy at Renmark Virtual Roadshow on July 28, 2026 - Kalkine Media
Phio Pharmaceuticals Appoints Dr. R. Todd Plott to Board of Directors, Strengthening Expertise in Dermatologic Research and Commercialization – Minichart - Minichart
Phio Pharmaceuticals appoints dermatologist to board By Investing.com - Investing.com South Africa
Phio Pharmaceuticals appoints dermatologist to board - Investing.com
Phio Pharmaceuticals adds dermatology expert to board - TipRanks
Phio Pharmaceuticals adds R. Todd Plott to its Board, joins Governance Committee - TradingView
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors - The Globe and Mail
Phio Pharmaceuticals (PHIO) Rises 3% to $1.03, Tests Key Resistance at $1.08TPO Profile - dars.gov.et
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision - EIN Presswire
Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones - Yahoo Finance
Phio Pharmaceuticals receives patent allowances in U.S., Canada, Japan By Investing.com - Investing.com Nigeria
Phio Pharmaceuticals receives patent allowances in U.S., Canada, Japan - Investing.com Canada
Phio's INTASYL patent portfolio consists of 54 issued patents - Stock Titan
Phio Pharmaceuticals Expands Global Patent Portfolio with Multiple Approvals in U.S., Canada, and Japan for INTASYL siRNA Technology - Kalkine Media
Enterprise value to EBITDA forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Phio Pharmaceuticals (PHIO) Slips Near Key Support at $0.95 – Technical AnalysisRisk Reward Setups - dars.gov.et
Price to book forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Phio Pharmaceuticals (PHIO) Slips 1.92% as Stock Tests Key Support at $0.97Sign of Strength - dars.gov.et
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
PHIO Q1 2026 Earnings: EPS Misses Estimates as Biotech Continues Clinical DevelopmentAnalyst Earnings Estimate - dars.gov.et
Phio Pharmaceuticals Corp. (PHIO) Q1 2026 Earnings: Wider-than-Expected Loss Reflects R&D InvestmentEPS Estimate Trend - dars.gov.et
PHIO PE Ratio & Valuation, Is PHIO Overvalued - Intellectia AI
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - TMX Newsfile
1.80%
1.77%
자본화:
|
볼륨(24시간):